Shin Nippon Biomedical Laboratories 향후 성장

Future 기준 점검 3/6

Shin Nippon Biomedical Laboratories (는) 각각 연간 10.1% 및 8.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 18.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.6% 로 예상됩니다.

핵심 정보

10.1%

이익 성장률

18.38%

EPS 성장률

Life Sciences 이익 성장	24.8%
매출 성장률	8.7%
향후 자기자본이익률	14.60%
애널리스트 커버리지	Low
마지막 업데이트	10 Nov 2025

최근 향후 성장 업데이트

Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 08

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings Seem To Be Promising

Nov 14

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Aug 18

Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 08

Shin Nippon Biomedical Laboratories (TSE:2395) Has Announced A Dividend Of ¥20.00

Jul 23

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥20.00

Jul 09

There May Be Some Bright Spots In Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings

May 15

Investors Continue Waiting On Sidelines For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Apr 28

Estimating The Intrinsic Value Of Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Apr 04

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Mar 05

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Feb 10

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Jan 10

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Dec 19

Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00

Dec 02

What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You

Nov 25

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Sep 19

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Aug 09

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Aug 06

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 26

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Jul 12

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27

이익 및 매출 성장 예측

TSE:2395 - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)
날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
3/31/2028	41,844	6,022	-3,450	7,155	2
3/31/2027	38,243	5,228	-5,248	5,848	2
3/31/2026	34,872	4,007	-2,700	8,062	2
9/30/2025	34,671	4,654	2,088	8,623	N/A
6/30/2025	33,342	5,063	N/A	N/A	N/A
3/31/2025	32,413	4,924	-3,897	7,035	N/A
12/31/2024	30,701	4,942	N/A	N/A	N/A
9/30/2024	27,074	3,896	-11,724	1,650	N/A
6/30/2024	26,195	4,280	N/A	N/A	N/A
3/31/2024	26,450	5,531	-6,498	2,106	N/A
12/31/2023	26,703	5,503	N/A	N/A	N/A
9/30/2023	26,626	4,607	-4,074	1,899	N/A
6/30/2023	26,848	5,489	N/A	N/A	N/A
3/31/2023	25,090	6,060	-950	4,004	N/A
12/31/2022	21,173	6,231	N/A	N/A	N/A
9/30/2022	20,135	8,043	4,382	7,170	N/A
6/30/2022	18,753	7,245	N/A	N/A	N/A
3/31/2022	17,748	7,127	4,339	5,952	N/A
12/31/2021	17,636	7,432	N/A	N/A	N/A
9/30/2021	16,068	6,025	4,075	5,301	N/A
6/30/2021	14,978	4,844	N/A	N/A	N/A
3/31/2021	15,110	3,661	3,629	4,746	N/A
12/31/2020	14,910	2,421	N/A	N/A	N/A
9/30/2020	15,175	2,812	1,389	2,706	N/A
6/30/2020	15,004	3,234	N/A	N/A	N/A
3/31/2020	14,561	2,550	1,788	3,018	N/A
12/31/2019	13,497	1,990	N/A	N/A	N/A
9/30/2019	13,167	1,915	1,784	2,988	N/A
6/30/2019	14,676	1,524	N/A	N/A	N/A
3/31/2019	15,658	1,950	N/A	2,892	N/A
12/31/2018	17,337	-49	N/A	N/A	N/A
9/30/2018	17,928	-993	N/A	2,943	N/A
6/30/2018	16,937	-2,566	N/A	N/A	N/A
3/31/2018	16,600	-3,555	N/A	1,344	N/A
12/31/2017	17,186	-1,072	N/A	N/A	N/A
9/30/2017	17,714	327	N/A	280	N/A
6/30/2017	17,230	260	N/A	N/A	N/A
3/31/2017	17,244	-915	N/A	-849	N/A
12/31/2016	15,880	-1,821	N/A	N/A	N/A
9/30/2016	15,269	-1,273	N/A	-3,109	N/A
6/30/2016	14,922	-1,475	N/A	N/A	N/A
3/31/2016	14,750	2,646	N/A	-3,339	N/A
12/31/2015	15,637	2,060	N/A	N/A	N/A
9/30/2015	16,344	401	N/A	-2,379	N/A
6/30/2015	17,164	1,546	N/A	N/A	N/A
3/31/2015	17,835	-1,385	N/A	-2,156	N/A
12/31/2014	18,058	-417	N/A	N/A	N/A

애널리스트 향후 성장 전망

수입 대 저축률: 2395 의 연간 예상 수익 증가율(10.1%)이 saving rate(0.6%)보다 높습니다.

수익 vs 시장: 2395 의 연간 수익(10.1%)이 JP 시장(7.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: 2395 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 2395 의 수익(연간 8.7%)이 JP 시장(연간 4.4%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: 2395 의 수익(연간 8.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: 2395의 자본 수익률은 3년 후 14.6%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/15 07:55
종가	2025/11/14 00:00
수익	2025/09/30
연간 수익	2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Shin Nippon Biomedical Laboratories, Ltd.는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Yuki Tsukamoto	BofA Global Research
Akitada Iwasa	Daiwa Securities Co. Ltd.
Stephen Barker	Jefferies LLC

Shin Nippon Biomedical Laboratories 향후 성장

Future 기준 점검 3/6

핵심 정보

최근 향후 성장 업데이트

Price target decreased by 8.3% to JP¥2,440

Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models

Consensus EPS estimates fall by 20%

Consensus EPS estimates increase by 21%

Price target increased by 74% to JP¥2,530

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings Seem To Be Promising

Price target decreased by 8.3% to JP¥2,440

Second quarter 2026 earnings released: EPS: JP¥19.23 (vs JP¥29.04 in 2Q 2025)

Upcoming dividend of JP¥20.00 per share

Now 21% overvalued after recent price rise

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2026 Results on Nov 07, 2025

Shin Nippon Biomedical Laboratories, Ltd. Recorded A 6.7% Miss On Revenue: Analysts Are Revisiting Their Models

New major risk - Financial position

Shin Nippon Biomedical Laboratories (TSE:2395) Has Announced A Dividend Of ¥20.00

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥20.00

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2026 Results on Aug 05, 2025

Consensus EPS estimates fall by 20%

There May Be Some Bright Spots In Shin Nippon Biomedical Laboratories' (TSE:2395) Earnings

Now 26% overvalued

New major risk - Share price stability

Full year 2025 earnings: EPS exceeds analyst expectations

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Investor sentiment improves as stock rises 24%

Investors Continue Waiting On Sidelines For Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Now 27% overvalued

Now 26% overvalued

Investor sentiment deteriorates as stock falls 17%

Estimating The Intrinsic Value Of Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395)

Upcoming dividend of JP¥30.00 per share

Consensus EPS estimates increase by 21%

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2025 Results on May 08, 2025

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Third quarter 2025 earnings released: EPS: JP¥45.01 (vs JP¥19.89 in 3Q 2024)

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Price target increased by 74% to JP¥2,530

Shin Nippon Biomedical Laboratories (TSE:2395) Will Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2025 Results on Feb 05, 2025

Shin Nippon Biomedical Laboratories (TSE:2395) Is Paying Out A Dividend Of ¥30.00

First half dividend of JP¥30.00 announced

Satsuma Pharmaceuticals, Inc. and Shin Nippon Biomedical Laboratories, Ltd. Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine with or Without Aura

What Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) 25% Share Price Gain Is Not Telling You

Second quarter 2025 earnings released: EPS: JP¥29.04 (vs JP¥38.27 in 2Q 2024)

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

Upcoming dividend of JP¥20.00 per share

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2025 Results on Nov 06, 2024

Earnings Miss: Shin Nippon Biomedical Laboratories, Ltd. Missed EPS By 88% And Analysts Are Revising Their Forecasts

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Shin Nippon Biomedical Laboratories, Ltd.'s (TSE:2395) Earnings As Shares Take 28% Pounding

Investor sentiment deteriorates as stock falls 21%

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2025 Results on Aug 06, 2024

Shin Nippon Biomedical Laboratories' (TSE:2395) Dividend Will Be ¥20.00

Final dividend of JP¥20.00 announced

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus EPS estimates fall by 19%

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Price target decreased by 13% to JP¥3,150

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 14%

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 17%